14. Commitments and Contingencies

Legal Proceedings

From time to time, the Company may become involved in legal proceedings, claims and investigations arising in the ordinary course of business. The Company evaluates such matters on a periodic basis and establishes accruals when losses are considered probable and reasonably estimable. As of September 30, 2026, except as described below, the Company was not a party to any material legal proceeding for which a loss contingency was required to be recorded or disclosed.

Section 205 Petition

On September 14, 2026, the Company filed a petition in the Delaware Court of Chancery pursuant to Section 205 of the DGCL seeking validation of the Certificate of Amendment to the Company's Third Amended and Restated Certificate of Incorporation filed with the Delaware Secretary of State on July 10, 2025, which effectuated the Company's one-for-twelve reverse stock split, and validation of all shares of the Company's common stock issued in reliance thereon. The matter is captioned In re NextCure, Inc., C.A. No. 2026-1203-JTL.

On November 2, 2026, the Delaware Court of Chancery entered a final order validating the Company's July 2025 reverse stock split amendment and all shares of common stock issued in reliance thereon. The matter has been resolved and no further action by the Company is required in connection with the proceeding. The Company did not record a liability in connection with the matter and the proceeding did not have a material impact on the Company's financial position, results of operations or cash flows.